Sanofi US News

Sanofi Statement on ACIP 2022-2023 Influenza Recommendations for People 65+

CAMBRIDGE, MA – June 22, 2022 – For the first time, the CDC’s Advisory Committee on Immunization Practices (ACIP) granted preferential recommendation for the use of differentiated flu vaccines for adults 65+. This recommendation affirms that all flu vaccines are not created equal, and that this vulnerable population requires better protection that a standard dose vaccine may not provide. 

Influenza is a serious illness that disproportionally impacts people 65+ and can lead to life-threatening complications, including pneumonia, serious heart conditions, hospitalizations and death. Now the world knows that differentiated flu vaccines can provide better protection for older adults.

Christopher Rizzo, MD 
U.S. Senior Medical Director at Sanofi 
“We are encouraged that the ACIP has recommended tailored influenza vaccines for adults 65+, and believe this is the first step in creating clearer guidance on protection against the flu for this high-risk population. We are hopeful this recommendation will mean more adults 65+ will be immunized with a flu vaccine that is best suited for their needs. Available clinical data and real-world evidence clearly support differentiated flu vaccines as being more effective than a standard dose vaccine at preventing influenza infection, helping to lower the burden of disease and minimize health disparities in the U.S. population. We look forward to a final decision from CDC. ” 

About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Evan Berland | + 1 215 432 0234 |
Sally Bain | + 1 781 264 1091 |
Kate Conway | + 1 617 981 2738 |

Sanofi Investor Relations
Eva Schaefer-Jansen | + 33 7 86 80 56 39 |
Arnaud Delépine | + 33 6 73 69 36 93 |
Corentine Driancourt | + 33 6 40 56 92 21 |  
Felix Lauscher | + 1 908 612 7239 |
Priya Nanduri | +1 617 764 6418 |  
Nathalie Pham | + 33 7 85 93 30 17 |


Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.  Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2021. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.